Cargando…

Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis

The anaerobic, gastrointestinal pathogen Clostridioides difficile can cause severe forms of enterocolitis which is mainly mediated by the toxins it produces. The RNA polymerase inhibitor Fidaxomicin is the current gold standard for the therapy of C. difficile infections due to several beneficial fea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brauer, Madita, Herrmann, Jennifer, Zühlke, Daniela, Müller, Rolf, Riedel, Katharina, Sievers, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739712/ https://www.ncbi.nlm.nih.gov/pubmed/34991700 http://dx.doi.org/10.1186/s13099-021-00475-9

Ejemplares similares

Clostridioides difficile Modifies its Aromatic Compound Metabolism in Response to Amidochelocardin-Induced Membrane Stress
por: Brauer, Madita, et al.
Publicado: (2022)

What’s a Biofilm?—How the Choice of the Biofilm Model Impacts the Protein Inventory of Clostridioides difficile
por: Brauer, Madita, et al.
Publicado: (2021)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

Differential View on the Bile Acid Stress Response of Clostridioides difficile
por: Sievers, Susanne, et al.
Publicado: (2019)

Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection
por: Heleno, Caio T, et al.
Publicado: (2021)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France
por: Guery, Benoit, et al.
Publicado: (2021)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

692. The Role of Fidaxomicin for the Treatment of Clostridioides Difficile Infection in the Pediatric Population in the United States
por: Lee, Yuman, et al.
Publicado: (2023)

In vitro reconstitution of α-pyrone ring formation in myxopyronin biosynthesis
por: Sucipto, H., et al.
Publicado: (2015)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Iron Regulation in Clostridioides difficile
por: Berges, Mareike, et al.
Publicado: (2018)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

Fidaxomicin for the Treatment of Clostridioides difficile Infection in Adult Patients: An Update on Results from Randomized Controlled Trials
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2022)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
por: Whitney, Laura, et al.
Publicado: (2023)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study
por: Wilcox, Mark H, et al.
Publicado: (2019)

797. Management of Patients with Multiple Clostridioides difficile Infection Recurrences using a Tapered-Pulsed Fidaxomicin Strategy
por: Tan, Xing, et al.
Publicado: (2020)

392. Guideline adaptation of fidaxomicin as first-line therapy for Clostridioides difficile infection in institutions across the United States
por: Basir, Angela, et al.
Publicado: (2022)

An Update on Clostridioides difficile Binary Toxin
por: Martínez-Meléndez, Adrián, et al.
Publicado: (2022)

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating Clostridioides difficile Infection and the Associated Recurrence Rate: A Retrospective Cohort Study
por: Mori, Nobuaki, et al.
Publicado: (2023)

668. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection in immunocompromised hosts, a single center study
por: Alsoubani, Majd, et al.
Publicado: (2023)

669. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience
por: Alsoubani, Majd, et al.
Publicado: (2023)

Characterization and Pharmacological Inhibition of the Pore-Forming Clostridioides difficile CDTb Toxin
por: Ernst, Katharina, et al.
Publicado: (2021)

Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production
por: Chilton, Caroline H., et al.
Publicado: (2016)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Structural dynamics of receptor recognition and pH-induced dissociation of full-length Clostridioides difficile Toxin B
por: Jiang, Mengqiu, et al.
Publicado: (2022)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

The prognostic value of toxin B and binary toxin in Clostridioides difficile infection
por: López-Cárdenas, Salvador, et al.
Publicado: (2021)

Host Immune Responses to Clostridioides difficile: Toxins and Beyond
por: Nibbering, Britt, et al.
Publicado: (2021)

Structure and conformational dynamics of Clostridioides difficile toxin A
por: Chen, Baohua, et al.
Publicado: (2022)

Non-Toxin-Based Clostridioides difficile Vaccination Approaches
por: Razim, Agnieszka, et al.
Publicado: (2023)

Diversity of binary toxin positive Clostridioides difficile in Korea
por: Kim, Jieun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_53mt849isq0o0d64nfts8ccglo